

Hyperlipidemia Drugs Market Analysis Report by Drug Class (Statins, PCSK9 Inhibitors, Bile Acid Sequestrants, Cholesterol Absorption Inhibitors, Fibric Acid Derivatives, Combination), and Segment Forecasts, 2016 - 2022

<https://marketpublishers.com/r/HD1EDECEA6BEN.html>

Date: July 2018

Pages: 98

Price: US\$ 5,950.00 (Single User License)

ID: HD1EDECEA6BEN

Abstracts

This report can be delivered to the clients within 120 Business Hours

The global hyperlipidemia drugs market size is expected reach USD 22.6 billion by 2022, according to a new report by Grand View Research, Inc., expanding at a CAGR of 2.3% during the forecast period. Several factors, such as increase in target population and growth in awareness about risk of cardiovascular diseases (CVD) due to persistent hypercholesterolemia, are stoking the growth of the market.

Hyperlipidemia is the most common type of dyslipidemia and is generally caused by abnormally high lipid levels in the blood. This condition can occur due to genetic factors (primary hyperlipidemia) as well as other factors such as poor diet and unhealthy lifestyle (secondary hyperlipidemia). Statins are the first line of treatment for secondary hyperlipidemia.

Target population of antihyperlipidemic drugs is broadly divided into statin users and nonstatin users. The revenue share of statin users has been declining. The nonstatin users segment consists of statin intolerant and nonresponsive population as well as familial hyperlipidemia (FH) population. Nonstatin users are seeking high-efficacy alternatives and this is anticipated to boost the revenue of this segment.

Upcoming patent expirations are expected to lead to greater genericization in the market, mostly among statins, cholesterol absorption inhibitors, and combination drugs.

However, new product launches are anticipated to continue to drive the market. Several novel mechanisms of action such as ACL inhibition, DGAT2 inhibition, and anti-ANGPTL-3 are being investigated for their potential for treatment of hyperlipidemia as well as for reducing the risk of CVD.

Further key findings from the report suggest:

Statins dominated the drug classes in 2016 owing to their high usage as the first line of therapy

Recent launch of PCSK9 inhibitors, such as Repatha and Praluent, is likely to change the current therapeutic scenario due to their improved efficacy and safety profile

PCSK9 inhibitors are expected to displace existing expensive therapies, lomitapide, and mipomersen for the treatment of homozygous FH patients

Europe was the leading regional market in 2016. It is estimated to maintain its dominance till 2022 owing to high prevalence of hypercholesterolemia

There are fewer growth opportunities in Japan due to unavailability of key pipeline drugs such as bempedoic acid

AstraZeneca; Merck & Co., Inc.; Pfizer, Inc.; DAIICHI SANKYO COMPANY, LIMITED; Amgen, Inc.; and Sanofi are some of the key players operating in this market

Amgen, Inc.; Sanofi; and Esperion are expected to have the highest shares in this market by 2022

Contents

CHAPTER 1 RESEARCH METHODOLOGY

- 1.1 Information procurement
- 1.2 Information or Data Analysis
 - 1.2.1 Market formulation & validation

CHAPTER 2 EXECUTIVE SUMMARY

- 2.1 Market Snapshot

CHAPTER 3 DISEASE PRIMER AND EPIDEMIOLOGY

- 3.1 Disease Primer
 - 3.1.1 Types:
 - 3.1.1.1 Type I
 - 3.1.1.2 Type II
 - 3.1.1.3 Type III
 - 3.1.1.4 Type IV
 - 3.1.1.5 Type V
 - 3.1.2 Complications
- 3.2 Epidemiology by Indications
- 3.3 Current Prevalence for Seven Major Markets (U.S., Japan, & EU5)
- 3.4 Current Incidence for Seven Major Markets (U.S., Japan, & EU5)
- 3.5 Forecast Prevalence and Incidence for Seven Major Markets (U.S., Japan, & EU5)

CHAPTER 4 GLOBAL HYPERLIPIDEMIA DRUGS MARKET OVERVIEW

- 4.1 Introduction and Market Overview
 - 4.1.1 Segmentation by region
 - 4.1.1.1 U.S.
 - 4.1.1.2 U.K.
 - 4.1.1.3 Germany
 - 4.1.1.4 Spain
 - 4.1.1.5 France
 - 4.1.1.6 Italy
 - 4.1.1.7 Japan
 - 4.1.2 Segmentation by drug class

- 4.1.2.1 Statins
- 4.1.2.2 Bile acid sequestrants
- 4.1.2.3 Cholesterol absorption inhibitors
- 4.1.2.4 Fibrin acid derivatives
- 4.1.2.5 PCSK9 inhibitors
- 4.1.2.6 Combination
- 4.1.2.7 Miscellaneous antihyperlipidemic agents
- 4.1.3 Market size & forecast
- 4.1.4 Sales performance
- 4.1.5 Market share distribution
- 4.1.6 Market dynamics among leading brands
- 4.2 Patent Expiry Schedule
- 4.3 Drivers and Challenges
- 4.4 M&A, Deal Landscape (2013 - 2017 YTD)
- 4.5 Pricing and Reimbursement
- 4.6 SWOT analysis

CHAPTER 5 HYPERLIPIDEMIA DRUGS MARKET: PIPELINE INTELLIGENCE

- 5.1 Pipeline Landscape
 - 5.1.1 Leading drugs in development
 - 5.1.2 Key R&D trends
 - 5.1.2.1 PCSK9 inhibition
 - 5.1.2.2 Antisense therapy
 - 5.1.2.3 Gene silencing
 - 5.1.2.4 Omega - 3 fatty acid
 - 5.1.2.5 ATP - citrate lyase
 - 5.1.2.6 DGAT2 inhibitor
 - 5.1.2.7 ANGPTL - 3 antibody
- 5.2 Promising Drugs in Pipeline
 - 5.2.1 Late stage pipeline and sales forecast
 - 5.2.2 Profile of disruptive drugs
 - 5.2.2.1 Repatha
 - 5.2.2.2 Praluent
 - 5.2.2.3 Bempedoic acid
 - 5.2.2.4 K - 877/Pemafibrate

CHAPTER 6 COMPANY PROFILES

6.1 AstraZeneca

- 6.1.1 Company overview
- 6.1.2 Current product portfolio
- 6.1.3 Product sales forecast through 2022
- 6.1.4 Key facts
 - 6.1.4.1 Crestor
 - 6.1.4.2 Epanova
- 6.1.5 Company - Key news flow
- 6.1.6 Pipeline view
- 6.1.7 Pipeline forecast
- 6.1.8 Catalysts and event calendar
- 6.1.9 SWOT analysis

6.2 Merck

- 6.2.1 Company overview
- 6.2.2 Current product portfolio
- 6.2.3 Product sales forecast through 2022
- 6.2.4 Key facts
 - 6.2.4.1 Zetia
 - 6.2.4.2 Zocor
 - 6.2.4.3 Vytorin
- 6.2.5 Company - Key news flow
- 6.2.6 Catalysts and event calendar
- 6.2.7 SWOT analysis

6.3 Pfizer

- 6.3.1 Company overview
- 6.3.2 Current product portfolio
- 6.3.3 Product sales forecast through 2022
- 6.3.4 Key facts
 - 6.3.4.1 Lipitor
 - 6.3.4.2 Caduet
- 6.3.5 Company - Key news flow
- 6.3.6 Pipeline view
- 6.3.7 Pipeline forecast
- 6.3.8 Catalysts and event calendar
- 6.3.9 SWOT analysis

6.4 Daiichi Sankyo

- 6.4.1 Company overview
- 6.4.2 Current product portfolio
- 6.4.3 Product sales forecast through 2022

6.4.4 Key facts

6.4.4.1 Welchol

6.4.4.2 Mevalotin

6.4.5 SWOT analysis

6.5 Amgen

6.5.1 Company overview

6.5.2 Current product portfolio

6.5.3 Product sales forecast through 2022

6.5.4 Key facts

6.5.4.1 Repatha

6.5.5 Company - Key news flow

6.5.6 Pipeline view

6.5.7 Pipeline forecast

6.5.8 SWOT analysis

6.6 Sanofi

6.6.1 Company overview

6.6.2 Current product portfolio

6.6.3 Product sales forecast through 2022

6.6.4 Key facts

6.6.4.1 Praluent

6.6.5 Company - Key news flow

6.6.6 Pipeline view

6.6.7 Pipeline forecast

6.6.8 Catalysts and event calendar

6.6.9 SWOT analysis

CHAPTER 7 MARKET OUTLOOK

7.1 What the future holds

7.2 Winners and Losers

7.3 Emerging Companies

7.4 The Road Ahead

List Of Tables

LIST OF TABLES

TABLE 1	Current hyperlipidemia prevalence for seven major markets - 2016
TABLE 2	Current hyperlipidemia incidence for seven major markets - 2016
TABLE 3	Forecast hyperlipidemia prevalence for seven major markets 2016 - 2022
TABLE 4	Forecast hyperlipidemia incidence for seven major markets 2016 - 2022
TABLE 5	Statin classification by intensity
TABLE 6	Hyperlipidemia drugs market size and forecast (in US million)
TABLE 7	Geographic sales performance by seven major markets (in US million)
TABLE 8	Hyperlipidemia drugs market by drug class (in US million)
TABLE 9	Forecast sales of leading brands (in US million)
TABLE 10	Global hyperlipidemia pipeline forecast
TABLE 11	Global hyperlipidemia pipeline sales forecast (in US million)
TABLE 12	Hyperlipidemia sales forecast by company (in US million)
TABLE 13	Hyperlipidemia drugs market share by company (in US million)
TABLE 14	Hyperlipidemia patent expiry schedule
TABLE 15	M&A, deal landscape
TABLE 16	Leading antihyperlipidemic drugs in pipeline
TABLE 17	Late-stage pipeline and sales forecast
TABLE 18	Profile of disruptive drug: Repatha
TABLE 19	Profile of disruptive drug: Praluent
TABLE 20	Profile of disruptive drug: Bempedoic Acid
TABLE 21	Profile of disruptive drug: Pemafibrate
TABLE 22	Product portfolio: Crestor
TABLE 23	Product portfolio: Epanova
TABLE 24	Crestor sales forecast through 2022
TABLE 25	AstraZeneca pipeline view
TABLE 26	AstraZeneca catalysts and event calendar
TABLE 27	Product portfolio: Zetia
TABLE 28	Product portfolio: Zocor
TABLE 29	Product portfolio: Vytorin
TABLE 30	Zetia sales forecast through 2022
TABLE 31	Zocor sales forecast through 2022
TABLE 32	Vytorin sales forecast through 2022
TABLE 33	Merck catalysts and event calendar
TABLE 34	Product portfolio: Lipitor
TABLE 35	Product portfolio: Caduet

TABLE 36	Lipitor sales forecast through 2022
TABLE 37	Caduet sales forecast through 2022
TABLE 38	Pfizer pipeline view
TABLE 39	Pfizer catalysts and event calendar
TABLE 40	Product portfolio: Welchol
TABLE 41	Product portfolio: Mevalotin
TABLE 42	Welchol sales forecast through 2022
TABLE 43	Product portfolio: Repatha
TABLE 44	Repatha sales forecast through 2022
TABLE 45	Amgen pipeline view
TABLE 46	Product portfolio: Praluent
TABLE 47	Praluent sales forecast through 2022
TABLE 48	Sanofi pipeline view
TABLE 49	Sanofi catalysts and event calendar

List Of Figures

LIST OF FIGURES

- FIG. 1 Market research process
- FIG. 2 Information procurement
- FIG. 3 Primary research pattern
- FIG. 4 Market research approaches
- FIG. 5 Value chain-based sizing & forecasting
- FIG. 6 QFD modelling for market share assessment
- FIG. 7 Market summary, 2016
- FIG. 8 Current prevalence for seven major markets - 2016
- FIG. 9 Current incidence for seven major markets - 2016
- FIG. 10 Market segmentation & scope
- FIG. 11 Geographic sales performance by seven major markets 2016
- FIG. 12 Hyperlipidemia drugs market by drug class
- FIG. 13 Hyperlipidemia market share by company 2016 - 2022
- FIG. 14 Market trends & outlook
- FIG. 15 Market driver relevance analysis (Current & future impact)
- FIG. 16 Market restraint relevance analysis (Current & future impact)
- FIG. 17 SWOT analysis (Hyperlipidemia drugs market)
- FIG. 18 SWOT analysis (AstraZeneca)
- FIG. 19 SWOT analysis (Merck)
- FIG. 20 SWOT analysis (Pfizer)
- FIG. 21 SWOT analysis (Daiichi Sankyo)
- FIG. 22 SWOT analysis (Amgen)
- FIG. 23 SWOT analysis (Sanofi)

I would like to order

Product name: Hyperlipidemia Drugs Market Analysis Report by Drug Class (Statins, PCSK9 Inhibitors, Bile Acid Sequestrants, Cholesterol Absorption Inhibitors, Fibric Acid Derivatives, Combination), and Segment Forecasts, 2016 - 2022

Product link: <https://marketpublishers.com/r/HD1EDECEA6BEN.html>

Price: US\$ 5,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/HD1EDECEA6BEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:

Last name:

Email:

Company:

Address:

City:

Zip code:

Country:

Tel:

Fax:

Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970